Soleno Therapeutics Cash And Equivalents vs. Total Debt

SLNO Stock  USD 52.71  3.13  5.61%   
Based on Soleno Therapeutics' profitability indicators, Soleno Therapeutics is yielding more profit at this time then in previous quarter. It has a moderate odds of reporting better profitability numbers in December. Profitability indicators assess Soleno Therapeutics' ability to earn profits and add value for shareholders. At this time, Soleno Therapeutics' Days Sales Outstanding is very stable compared to the past year. As of the 30th of November 2024, Operating Cash Flow Sales Ratio is likely to grow to 0.01, though Price To Sales Ratio is likely to grow to (0.01). At this time, Soleno Therapeutics' Total Other Income Expense Net is very stable compared to the past year. As of the 30th of November 2024, Income Tax Expense is likely to grow to about 2.8 M, though Operating Income is likely to grow to (39.3 M).
For Soleno Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Soleno Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Soleno Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Soleno Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Soleno Therapeutics over time as well as its relative position and ranking within its peers.
  
Check out World Market Map.
To learn how to invest in Soleno Stock, please use our How to Invest in Soleno Therapeutics guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Soleno Therapeutics. If investors know Soleno will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Soleno Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.79)
Return On Assets
(0.48)
Return On Equity
(0.91)
The market value of Soleno Therapeutics is measured differently than its book value, which is the value of Soleno that is recorded on the company's balance sheet. Investors also form their own opinion of Soleno Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Soleno Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Soleno Therapeutics' market value can be influenced by many factors that don't directly affect Soleno Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Soleno Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Soleno Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Soleno Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Soleno Therapeutics Total Debt vs. Cash And Equivalents Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Soleno Therapeutics's current stock value. Our valuation model uses many indicators to compare Soleno Therapeutics value to that of its competitors to determine the firm's financial worth.
Soleno Therapeutics is rated below average in cash and equivalents category among its peers. It is rated below average in total debt category among its peers making up about  0.02  of Total Debt per Cash And Equivalents. The ratio of Cash And Equivalents to Total Debt for Soleno Therapeutics is roughly  59.73 . As of the 30th of November 2024, Total Debt To Capitalization is likely to grow to 0. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Soleno Therapeutics' earnings, one of the primary drivers of an investment's value.

Soleno Total Debt vs. Cash And Equivalents

Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.

Soleno Therapeutics

Cash

 = 

Bank Deposits

+

Liquidities

 = 
24.07 M
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.

Soleno Therapeutics

Total Debt

 = 

Bonds

+

Notes

 = 
403 K
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.

Soleno Total Debt vs Competition

Soleno Therapeutics is rated below average in total debt category among its peers. Total debt of Health Care industry is at this time estimated at about 284.7 Million. Soleno Therapeutics adds roughly 403,000 in total debt claiming only tiny portion of equities under Health Care industry.
Total debt  Capitalization  Revenue  Valuation  Workforce

Soleno Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Soleno Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Soleno Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Soleno Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Soleno Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Operating Income-41.4 M-39.3 M
Income Before Tax-39 M-37 M
Total Other Income Expense Net2.4 M2.5 M
Net Loss-39 M-37 M
Income Tax Expense2.7 M2.8 M
Net Loss-33.2 M-34.8 M
Non Operating Income Net Other13.4 M14.1 M
Net Loss-21.7 M-22.7 M
Net Interest Income559 K587 K
Interest Income559 K321.2 K
Change To Netincome1.9 M1.2 M
Net Loss(2.36)(2.48)
Income Quality 0.64  0.58 
Net Income Per E B T 0.97  1.08 

Soleno Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Soleno Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Soleno Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Soleno Therapeutics' important profitability drivers and their relationship over time.

Use Soleno Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Soleno Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Soleno Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Soleno Therapeutics Pair Trading

Soleno Therapeutics Pair Trading Analysis

The ability to find closely correlated positions to Soleno Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Soleno Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Soleno Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Soleno Therapeutics to buy it.
The correlation of Soleno Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Soleno Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Soleno Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Soleno Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Soleno Therapeutics position

In addition to having Soleno Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Non-Metallic and Industrial Metal Mining Thematic Idea Now

Non-Metallic and Industrial Metal Mining
Non-Metallic and Industrial Metal Mining Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Non-Metallic and Industrial Metal Mining theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Non-Metallic and Industrial Metal Mining Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Soleno Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Soleno Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Soleno Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Soleno Therapeutics Stock:
Check out World Market Map.
To learn how to invest in Soleno Stock, please use our How to Invest in Soleno Therapeutics guide.
You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
To fully project Soleno Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Soleno Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Soleno Therapeutics' income statement, its balance sheet, and the statement of cash flows.
Potential Soleno Therapeutics investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Soleno Therapeutics investors may work on each financial statement separately, they are all related. The changes in Soleno Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Soleno Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.